BioInvent International
23.11.2021 17:38:03 CET | ACCESS Newswire | Press release
LUND, SE / ACCESSWIRE / November 23, 2021 / BioInvent International (STO:BINV)
Friday, December 17 at 1 pm ET (7 pm CET)
BI-1206 is a Potential Treatment for non-Hodgkin's Lymphoma and Solid Tumors
BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced that it will host a key opinion leader (KOL) webinar on BI-1206, a potential treatment for non-Hodgkin's lymphoma and solid tumors, on Friday, December 17, 2021 at 1:00pmET/7:00pmCET.
The webcast will feature KOL Michael Wang, M.D., from the MD Anderson Cancer Center, who will discuss the current treatment landscape and unmet medical need in treating patients with non-Hodgkin's lymphoma (NHL) and Mantle Cell Lymphoma (MCL).
BioInvent's management team will provide an update on the ongoing BI-1206 clinical studies for the treatment of non-Hodgkin's lymphoma and solid tumors, including an overview of the NHL data presented at ASH on December 11.
BI-1206 is BioInvent's lead drug candidate and is currently being investigated in two trials. One is evaluating the BI-1206 combination with rituximab for the treatment of non-Hodgkin's lymphoma; and the other evaluates BI-1206 in combination with anti-PD1 therapy Keytruda® (pembrolizumab) in solid tumors.
BI-1206 is a monoclonal antibody that selectivity binds to FcγRIIB (CD32B). By blocking FcγRIIB, BI-1206 can recover and enhance the activity of rituximab or other anti-CD20 monoclonal antibodies in the treatment of NHL. In addition, BI-1206 has the potential to reduce resistance to PD-1 immune checkpoint blockade, providing a new way to enhance anti-tumor immune responses in patients with solid tumors.
To register for the event, please click here.
Luhua (Michael) Wang, M.D. is a Professor in the department of Lymphoma & Myeloma at MD Anderson. Dr. Wang obtained his M.D. from Shandong Medical University and M.S. from Beijing University, Medical School. He completed his clinical training as a resident at Norwalk Hospital, Norwalk, Connecticut, and as a Fellow in Oncology and in Hematology at MD Anderson.
Dr. Wang has published more than 150 peer-reviewed papers and presented his work at meetings nationally and internationally. He is the current Director of Mantle Cell Lymphoma (MCL) Program of Excellence and Co-Director of Clinical Trials at MD Anderson.
During the past 15 years, he has focused on preclinical and clinical research and established an MCL-SCID-hu mouse model, which is the first human primary MCL animal model for the study of the biology and treatment of MCL. Dr. Wang has pioneered the work to improve the treatment of patients with MCL, including the introduction of BTK inhibitors such as ibrutinib and acalabrutinib in the treatment algorithm, and has performed extensive work with CAR-T cells for the treatment of these patients. His work has been published in the most prestigious medical journals such as the NEJM and the Lancet. He is currently the PI of the B-Cell Lymphoma Moon Shot Program at MD Anderson.
About BioInvent
BioInvent International AB (Nasdaq Stockholm:BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently three drug candidates in four ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The Company's validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company's own clinical development pipeline or for additional licensing and partnering.
The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at www.bioinvent.com. Follow on Twitter: @BioInvent.
For further information, please contact:
Cecilia Hofvander
Senior Director Investor Relations
+46 (0)46 286 85 50
cecilia.hofvander@bioinvent.com
BioInvent International AB (publ)
Co. Reg. No. Org nr: 556537-7263
Visiting address: Ideongatan 1
Mailing address: 223 70 LUND
Phone: +46 (0)46 286 85 50
www.bioinvent.com
The press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as the date they are made and are, by their very nature, in the same way as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.
Attachments
BioInvent Hosting Key Opinion Leader Webinar on BI-1206
SOURCE: BioInvent International
View source version on accesswire.com:
https://www.accesswire.com/674388/BioInvent-Hosting-Key-Opinion-Leader-Webinar-on-BI-1206
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
U.S. Polo Assn. Expands Collegiate Partnership Program to Record 70 Teams for 2026 Season5.3.2026 13:00:00 CET | Press release
WEST PALM BEACH, FLA. / ACCESS Newswire / March 5, 2026 / U.S. Polo Assn., the official sports brand of the United States Polo Association (USPA), proudly announces the continued expansion of its Collegiate Partnership Program (CPP) for the 2026 season and academic year. Now in its eighth consecutive year, the program reaches a historic milestone by supporting 70 collegiate teams across 31 universities nationwide, the largest number of teams ever participating in the program.U.S. Polo Assn.'s Collegiate Partnership Program featuring the California Polytechnic State University Women's and Men's Polo Teams Photo Credit: California Polytechnic State University Polo Teams U.S. Polo Assn. will outfit hundreds of student-athletes from coast to coast, including small private and large public institutions, Ivy League Universities, and Historically Black Colleges and Universities (HBCUs). The CPP supports 35 women's and 35 men's teams, reinforcing U.S. Polo Assn.'s long-standing commitment to g
British Library Selects Preservica for Large-Scale Digital Preservation Program4.3.2026 15:00:00 CET | Press release
OXFORD, UK AND BOSTON, MA / ACCESS Newswire / March 4, 2026 / Preservica, the leader in AI-powered Active Digital Preservation™, today announced that it has been selected by the British Library to provide a Digital Preservation Repository solution and project implementation services to support the long-term preservation and management of the Library's extensive, petabyte- scale digital collections. Following a formal procurement and evaluation process, Preservica will deliver a secure, cloud-based Digital Preservation platform to support the continuous acquisition, management, and long-term preservation of the Library's diverse and expanding digital collections - including e-books, e-journals, sound recordings, UK websites, eTheses, digitised heritage materials and more - strengthening its ability to safeguard digital content for future generations. "Robust and secure Digital Preservation is essential for the effective custodianship, management and long-term readability of modern digit
Accu-Time Systems Announces Strategic Integration with Connecteam for Seamless Workforce Management4.3.2026 15:00:00 CET | Press release
The collaboration brings enterprise-grade stride80 time clocks to the Connecteam ecosystem, offering businesses a unified solution for high-accuracy attendance and real-time data sync. BOSTON, MASSACHUSETTS / ACCESS Newswire / March 4, 2026 / Accu-Time Systems (ATS), a leading provider of employee time collection solutions, today announced a strategic partnership with Connecteam, the all-in-one platform for managing distributed workforces. This collaboration integrates Connecteam's workforce management system with Accu-Time Systems' stride80 employee time clocks-delivering a unified, accurate, and secure way to collect employee time for payroll processing. Through this integration, employee punches recorded on stride80 time clocks are automatically transmitted to Connecteam's time tracking system in real time. The result is a streamlined data flow that eliminates manual entry, reduces payroll errors, and saves organizations valuable administrative time. "By integrating Connecteam's pla
Formerra Appoints Tom Kelly as Chief Executive Officer4.3.2026 14:00:00 CET | Press release
CLEVELAND, OHIO / ACCESS Newswire / March 4, 2026 / Formerra, LLC ("Formerra"), a leading distributor of engineered thermoplastic resins, additives, elastomers, and other specialty materials, today announced the appointment of Tom Kelly as Chief Executive Officer ("CEO"). A seasoned executive with over 30 years of specialty and engineered materials experience, Tom is known for leading teams to drive differentiated growth and building high-performing organizations set up for long-term success. The former CEO, Cathy Dodd, will stay on as Special Advisor to the Board and will remain an investor in the Company. Tom brings extensive commercial, supply chain, and distribution experience with a strong background in scaling global enterprises in the engineered materials sector. After previous roles at Cabot Microelectronics and Chemtura, Tom's most recent role was Senior Vice President of Engineered Materials at Celanese, where he led key commercial and operational initiatives across engineere
New GTDC Research Details Distribution's Influence on AI, Cloud and Hyperscaler Sales and Adoption3.3.2026 16:00:00 CET | Press release
IT distributors have become digital ecosystem orchestrators that unify cloud, AI, hyperscaler, and subscription-based business models. Distribution significantly accelerates vendor growth while reducing risk, allowing suppliers to scale efficiently, expand partner bases, enter new markets and mitigate financial and operational liabilities. Digital platforms are creating a new GTM "operating system". These systems offer end-to-end digital commerce and intelligence layers to manage procurement, billing, lifecycles and analytics. TAMPA, FL / ACCESS Newswire / March 3, 2026 / The Global Technology Distribution Council (GTDC), the world's largest consortium of technology distributors, has released a new research report, Distribution: The Digital Force Multiplier. Developed by CommCentric Solutions, this study examines how IT distribution has transformed and continues to evolve into a critical enabler of cloud, artificial intelligence (AI), hyperscaler and platform-driven business models acr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom